ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines (Q36968280)

17 August 2017

1 reference

title

ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines (English)

1 reference

17 August 2017

1 reference

Debbie Drane

1

1 reference

17 August 2017

Charmaine Gittleson

series ordinal

2

1 reference

17 August 2017

Jeff Boyle

series ordinal

3

1 reference

17 August 2017

Eugene Maraskovsky

series ordinal

4

1 reference

17 August 2017

1 October 2007

1 reference

Expert Review of Vaccines

17 August 2017

1 reference

17 August 2017

6

1 reference

17 August 2017

761-772

1 reference

17 August 2017

5

1 reference

Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses.

17 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.761

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.761

Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.761

On the preparation, microscopic investigation and application of ISCOMs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.761

ISCOM based vaccines for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.761

Association of antigens to ISCOMATRIX adjuvant using metal chelation leads to improved CTL responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.761

Recent advances in the discovery and delivery of vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.761

NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.761

Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.761

Dendritic cell maturation enhances CD8+ T-cell responses to exogenous antigen via a proteasome-independent mechanism of major histocompatibility complex class I loading

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.761

The utility of ISCOMATRIX adjuvant for dose reduction of antigen for vaccines requiring antibody responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.761

Therapeutic vaccines for chronic infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.761

Immune responses to ISCOM formulations in animal and primate models

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.761

Cytotoxic T cell polyepitope vaccines delivered by ISCOMs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.761

Cancer/testis antigens: an expanding family of targets for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.761

ISCOMATRIX adjuvant for antigen delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.761

Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.761

21 January 2018

Identifiers

DOI

10.1586/14760584.6.5.761

1 reference

17 August 2017

1 reference